Antares Pharma (NASDAQ:ATRS) Given Daily Coverage Optimism Rating of 0.21
News articles about Antares Pharma (NASDAQ:ATRS) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Antares Pharma earned a news impact score of 0.21 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 45.6513494394336 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Trade Signal Alert For Antares Pharma Inc (ATRS) Shares – Evergreen Caller (evergreencaller.com)
- Shares Running on Volume: Vanstar Mining Resources Inc (VSR.V) – Evergreen Caller (evergreencaller.com)
- Antares Pharma to Report Second Quarter 2017 Financial and Operating Results and Host Webcast and Conference Call – GlobeNewswire (press release) (globenewswire.com)
ATRS has been the subject of several research reports. Vetr upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price target for the company in a research report on Wednesday, July 5th. Piper Jaffray Companies set a $4.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a research report on Wednesday, July 26th. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Antares Pharma in a research report on Friday, June 23rd. Raymond James Financial, Inc. initiated coverage on shares of Antares Pharma in a research report on Thursday, April 20th. They set a “strong-buy” rating and a $4.30 price target for the company. Finally, Chardan Capital initiated coverage on shares of Antares Pharma in a research report on Friday, June 23rd. They set a “buy” rating and a $5.00 price target for the company. One investment analyst has rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company. Antares Pharma currently has an average rating of “Buy” and a consensus price target of $3.83.
Antares Pharma (NASDAQ ATRS) traded down 0.32% during trading on Monday, reaching $3.11. 1,328,646 shares of the company traded hands. The company’s 50-day moving average price is $3.12 and its 200 day moving average price is $2.73. The firm’s market capitalization is $484.93 million. Antares Pharma has a 52 week low of $1.01 and a 52 week high of $3.37.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. Antares Pharma had a negative return on equity of 43.86% and a negative net margin of 39.44%. The company had revenue of $12.01 million during the quarter, compared to the consensus estimate of $12.10 million. On average, equities research analysts expect that Antares Pharma will post ($0.13) EPS for the current year.
In other Antares Pharma news, insider Fred M. Powell acquired 130,000 shares of Antares Pharma stock in a transaction that occurred on Friday, June 9th. The stock was bought at an average cost of $2.79 per share, for a total transaction of $362,700.00. Following the acquisition, the insider now owns 331,434 shares of the company’s stock, valued at $924,700.86. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 11.60% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Antares Pharma (NASDAQ:ATRS) Given Daily Coverage Optimism Rating of 0.21” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/07/antares-pharma-nasdaqatrs-given-daily-coverage-optimism-rating-of-0-21.html.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.